Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10177092 | 0.81 | CNR2 (0.43) | CNR2CNR1 | |
| SCHEMBL766752 | 0.78 | CNR2 (0.47) | CNR2CNR1 | |
| SCHEMBL12289489 | 0.76 | CNR2 (0.46) | CNR2CNR1 | |
| SCHEMBL352817 | 0.76 | CNR2 (0.52) | CNR2CNR1 | |
| SCHEMBL10147821 | 0.75 | CNR2 (0.40) | CNR2CNR1 | |
| SCHEMBL469278 | 0.74 | CNR2 (0.38) | CNR2CNR1 | |
| SCHEMBL10146289 | 0.73 | CNR2 (0.41) | CNR2CNR1 | |
| SCHEMBL469435 | 0.72 | CNR2 (0.38) | CNR2CNR1 | |
| SCHEMBL10146087 | 0.72 | CNR2 (0.39) | CNR2CNR1 | |
| SCHEMBL18638816 | 0.72 | CNR2 (0.39) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2418207-A1 | Sulfone compounds which modulate the CB2 receptor | Boehringer Ingelheim International GmbH (DE) | 2012-02-15 | — | — | EP | disclosed |
| US-20120015988-A1 | Sulfone Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015988-A1 | Sulfone Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, TRPV1 | CNR2 1/4885CNR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.